Specifications of Biopharmaceutical Products
Online Training Id: GMP-009
Geographical Region: Global
Duration: 2 hrs
This lecture provides general principles on the setting and justification, of a uniform set of international Specifications for biotechnological and biological products to support new marketing applications, so that when tested according to the listed analytical procedures, will meet the acceptance criteria. Specifications are critical quality standards that are proposed and justified by the manufacturer and approved by regulatory authorities as conditions of approval.
This course will provide the competencies required to set specifications and will detail the Characterization of a biotechnological or biological product (which includes the determination of physicochemical properties, biological activity, immunochemical properties, purity and impurities) by appropriate techniques is necessary to allow such relevant specifications to be established;
General Concepts of setting specifications.
Critical to Establishing Specifications.
Common Specification Considerations (Acceptance criteria should be established and justified based on data obtained from lots used in preclinical and/or clinical studies, data from lots used for demonstration of manufacturing consistency and data from stability studies, and relevant development data).
Thomas G. (Gary) Bird, Ph.D. is co-founder of PharmaConsult Global, Ltd., an international cooperative supplying GXP quality consulting services and President, PharmaConsult-US, LLC. He served as Director of Corporate Quality for GTx, Inc. (Memphis, TN, USA) from 2003 until 2013 and was responsible for confirming all non-clinical (GLP), manufacturing (GMP), and clinical trial (GCP) related activities were conducted in compliance with appropriate laws and regulations.
He developed all Quality Systems to support the growth of the small pharmaceutical company and led an NDA submission team. Prior to joining GTx, he was with Eli Lilly and Company from 1995 to 2003, serving as Senior Quality Advisor for Biotechnology in Corporate Quality Assurance and Senior Regulatory Consultant, CMC Regulator Affairs.
He was with the FDA from 1990 to 1995 in both CDER and CBER where he was Assistant to the Deputy Director. During his time with Lilly and FDA he represented both PhRMA and the FDA in the International Conference on Harmonization negotiations on four (4) different agreed guidances.
He approved and signed documents on behalf of both organizations. He was secretary for all ICH Working Committees for documents on which he worked including Biotech Stability (Q5C), Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process (Q5E); Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products (Q6B) and The Common Technical Document for CMC Submissions (M4). Dr. Bird holds a Ph.D. in Biochemistry/Entomology from Mississippi State University.
Dr. Gary Bird PH.D.